|

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

RECRUITINGSponsored by VA Office of Research and Development
Actively Recruiting
SponsorVA Office of Research and Development
Started2024-09-19
Est. completion2027-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07019844

Summary

This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients age \>18 years from the VA medical system
* Treatment-naïve patients with HCC with BCLC B or C disease

Exclusion Criteria:

* Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
* Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years

Conditions4

CancerHepatocellular Carcinoma (HCC)Liver CancerLiver Disease

Locations1 site

Miami VA Healthcare System, Miami, FL
Miami, Florida, 33125
Binu V John, MD MPH305-575-7000binu.john@va.gov

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.